• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三碘甲状腺原氨酸撤药时间对甲状腺癌甲状腺切除术后131I摄取的影响。

Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer.

作者信息

Goldman J M, Line B R, Aamodt R L, Robbins J

出版信息

J Clin Endocrinol Metab. 1980 Apr;50(4):734-9. doi: 10.1210/jcem-50-4-734.

DOI:10.1210/jcem-50-4-734
PMID:7364930
Abstract

Radioiodine uptake by thyroid remnants and metastases postthyroidectomy for thyroid cancer is increased by withdrawing thyroid hormone, which raises TSH levels. The minimal withdrawal time for maximal uptake is unknown. Therefore, we performed 33 studies in 27 patients after 2 weeks and again after 4 weeks of T3 withdrawal. We examined cervical (or pulmonary) uptake and whole body scanning at 48 h and whole body retention at 48, 72, and 96 h after radioiodine. In 4 studies, only physiological nonthyroidal activity was seen on both scans. Cervical uptake was low in these 4 studies. Of the remaining 29 studies with thyroid activity on both scans, 4 had high cervical uptakes after 2 weeks, which decreased by 4 weeks to less than 50% of the 2 week value. The same trend was seen in whole body retentions. In 2 studies, the uptake increased at 4 weeks compared to that at 2 weeks, but the change was small and was reflected in whole body retention of only 1 of these subjects. In 23 studies, including 6 with metastatic disease, the individual uptakes and whole body retentions were similar after 2 and 4 weeks. The mean uptakes and retentions also did not differ despite significantly higher (P less than 0.001) TSH values at 4 weeks. All definite areas of localization of radioactivity seen on the scans after 4 weeks were seen after 2 weeks. Therefore, radioiodine uptake, scanning, and therapy should be performed after 2 weeks of T3 withdrawal when patients are minimally hypothyroid. Serum TSH should also be measured to identify the rare individual not responding to brief T3 withdrawal.

摘要

甲状腺癌甲状腺切除术后,停用甲状腺激素可使甲状腺残留组织和转移灶对放射性碘的摄取增加,这会提高促甲状腺激素(TSH)水平。达到最大摄取的最短停药时间尚不清楚。因此,我们对27例患者进行了33项研究,分别在停用T3 2周和4周后进行。我们在放射性碘注射后48小时检查颈部(或肺部)摄取及全身扫描,并在48、72和96小时检查全身滞留情况。在4项研究中,两次扫描均仅见生理性非甲状腺活动。这4项研究中颈部摄取较低。在其余29项两次扫描均有甲状腺活动的研究中,4项在2周后颈部摄取较高,到4周时降至2周值的50%以下。全身滞留情况也呈现相同趋势。在2项研究中,与2周时相比,4周时摄取增加,但变化较小,仅在其中1例受试者的全身滞留情况中有所体现。在23项研究中,包括6项有转移疾病的研究,2周和4周后的个体摄取及全身滞留情况相似。尽管4周时TSH值显著更高(P<0.001),但平均摄取和滞留情况并无差异。4周后扫描上可见的所有明确放射性定位区域在2周后也可见。因此,当患者处于轻度甲状腺功能减退状态时,应在停用T3 2周后进行放射性碘摄取、扫描及治疗。还应检测血清TSH,以识别罕见的对短期停用T3无反应的个体。

相似文献

1
Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer.三碘甲状腺原氨酸撤药时间对甲状腺癌甲状腺切除术后131I摄取的影响。
J Clin Endocrinol Metab. 1980 Apr;50(4):734-9. doi: 10.1210/jcem-50-4-734.
2
Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine.血清促甲状腺激素和甲状腺激素检测在放射性碘治疗甲状腺癌中的应用
Br J Radiol. 1977 Nov;50(599):799-807. doi: 10.1259/0007-1285-50-599-799.
3
Timing of Hormone Withdrawal in Children Undergoing 131I Whole-Body Scans for Thyroid Cancer.接受甲状腺癌碘-131全身扫描的儿童中激素撤停的时机
Horm Res Paediatr. 2016;86(6):410-415. doi: 10.1159/000453064. Epub 2016 Dec 1.
4
Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?使用重组人促甲状腺素进行诊断性碘-131扫描对甲状腺切除术后分化型甲状腺癌的随访是否有用?
J Clin Endocrinol Metab. 2002 Apr;87(4):1490-8. doi: 10.1210/jcem.87.4.8338.
5
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.甲状腺癌放射性碘治疗中的碘生物动力学与剂量学:促甲状腺激素释放激素(rhTSH)或激素撤减后消融的前瞻性国际对照研究的程序与结果
J Nucl Med. 2006 Apr;47(4):648-54.
6
Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.甲状腺癌患者在甲状腺激素剥夺状态下及使用重组人促甲状腺素时肿瘤组织与非肿瘤组织碘摄取情况的比较。
Clin Endocrinol (Oxf). 2006 Oct;65(4):519-23. doi: 10.1111/j.1365-2265.2006.02626.x.
7
Effects of oral thyrotropin-releasing hormone, exogenous thyroid-stimulating hormone, and withdrawal of triiodothyronine on 131I uptake after subtotal thyroidectomy.口服促甲状腺激素释放激素、外源性促甲状腺激素以及停用三碘甲状腺原氨酸对甲状腺次全切除术后¹³¹I摄取的影响。
J Clin Endocrinol Metab. 1980 Mar;50(3):502-6. doi: 10.1210/jcem-50-3-502.
8
Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.重组人促甲状腺素刺激后用30毫居里放射性碘治疗甲状腺癌:对术后残留组织消融的有效性以及左旋甲状腺素中碘含量在消融结果中的可能作用。
J Clin Endocrinol Metab. 2003 Sep;88(9):4110-5. doi: 10.1210/jc.2003-030298.
9
Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal.循环脂联素浓度与甲状腺激素去除后甲状腺癌患者的游离甲状腺素水平相关。
Metabolism. 2010 Feb;59(2):195-9. doi: 10.1016/j.metabol.2009.06.032. Epub 2009 Sep 17.
10
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.低危分化型甲状腺癌患者在重组人促甲状腺激素或甲状腺激素停药后行甲状腺残留术后碘-131 清甲治疗的随访。
J Clin Endocrinol Metab. 2009 Nov;94(11):4171-9. doi: 10.1210/jc.2009-0869. Epub 2009 Oct 22.

引用本文的文献

1
RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer.重组人促甲状腺激素在分化型甲状腺癌患者动态评估中的应用
Eur J Nucl Med Mol Imaging. 2025 Jun 9. doi: 10.1007/s00259-025-07349-1.
2
Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II.分化型甲状腺癌的放射性碘治疗:从核医学角度看韩国甲状腺协会2024年指南总结,第二部分
Nucl Med Mol Imaging. 2025 Feb;59(1):8-26. doi: 10.1007/s13139-024-00886-x. Epub 2024 Nov 1.
3
Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase I/II study.
新型重组人促甲状腺激素在辅助分化型甲状腺癌患者术后评估中的应用:I/II 期研究。
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4171-4181. doi: 10.1007/s00259-022-05865-y. Epub 2022 Jul 4.
4
Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal.L-三碘甲状腺原氨酸在甲状腺激素治疗停药患者中的药代动力学。
Thyroid. 2019 Oct;29(10):1371-1379. doi: 10.1089/thy.2019.0101. Epub 2019 Sep 12.
5
Differentiated thyroid cancer theranostics: radioiodine and beyond.分化型甲状腺癌的诊疗一体化:放射性碘及其他
Br J Radiol. 2018 Nov;91(1091):20180136. doi: 10.1259/bjr.20180136. Epub 2018 Oct 11.
6
Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?分化型甲状腺癌消融成功是否需要非常高的促甲状腺激素水平?
Mol Imaging Radionucl Ther. 2016 Jun 5;25(2):79-84. doi: 10.4274/mirt.88598.
7
Radioiodine Remnant Ablation: A Critical Review.放射性碘残留消融:批判性综述。
World J Nucl Med. 2015 Sep-Dec;14(3):144-55. doi: 10.4103/1450-1147.163240.
8
Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.研究重组人促甲状腺素预激¹³¹I治疗方案用于转移性分化型甲状腺癌患者:与传统甲状腺激素撤停方案的比较。
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1767-80. doi: 10.1007/s00259-014-2737-3. Epub 2014 Apr 1.
9
In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.在甲状腺癌行甲状腺切除术的患者中,甲状腺素停药后血清促甲状腺激素达到 30μU/mL 并不总是足以检测到升高的刺激后血清甲状腺球蛋白。
Thyroid. 2013 Feb;23(2):185-93. doi: 10.1089/thy.2012.0327.
10
Rational management of differentiated thyroid cancer.分化型甲状腺癌的合理管理
Malays J Med Sci. 2006 Jul;13(2):45-51.